Further, pharmacological blockade of the CXCR4/CXCL12 axis results in chemosensitization of AML cells in vitro and in vivo, therefore serving as a biological basis for development of various CXCR4 and CXCL12 inhibitors [13–16]. Here, CXCL12 is linked to acute myeloid leukemia.